Pure Biologics Spólka Akcyjna

Warsaw Stock Exchange PUR.WA

Pure Biologics Spólka Akcyjna EBIT for the year ending December 31, 2023: USD -8.08 M

Pure Biologics Spólka Akcyjna EBIT is USD -8.08 M for the year ending December 31, 2023, a -40.06% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Pure Biologics Spólka Akcyjna EBIT for the year ending December 31, 2022 was USD -5.77 M, a -123.08% change year over year.
  • Pure Biologics Spólka Akcyjna EBIT for the year ending December 31, 2021 was USD -2.59 M, a 15.33% change year over year.
  • Pure Biologics Spólka Akcyjna EBIT for the year ending December 31, 2020 was USD -3.05 M, a -198.12% change year over year.
  • Pure Biologics Spólka Akcyjna EBIT for the year ending December 31, 2019 was USD -1.02 M, a -468.35% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
Warsaw Stock Exchange: PUR.WA

Pure Biologics Spólka Akcyjna

CEO Dr. Filip Jelen M.B.A., Ph.D.
IPO Date Dec. 1, 2018
Location Poland
Headquarters ul. Dunska 11
Employees 4
Sector Health Care
Industries
Description

Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.

Similar companies

CTX.WA

Captor Therapeutics Spolka Akcyjna

USD 10.54

0.97%

SLV.WA

Selvita S.A.

USD 11.11

-3.75%

SNT.WA

Synektik Spólka Akcyjna

USD 50.91

0.74%

RVU.WA

Ryvu Therapeutics S.A.

USD 7.78

-9.75%

MOC.WA

Molecure S.A.

USD 2.23

1.07%

StockViz Staff

January 16, 2025

Any question? Send us an email